Effectiveness of herbal capsule in COVID-19
Phase 3
Recruiting
- Conditions
- COVID-19.COVID-19U07.1
- Registration Number
- IRCT20200330046899N1
- Lead Sponsor
- Kerman University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Patients who require hospitalization based on national guidelines for diagnosis and treatment of COVID-19 and need to start drugs.
18 to 75 years of age for both sexes
The patient's ability to fill out an informed consent form to enter the study
Exclusion Criteria
Pregnancy and lactation
History of allergy to any of the components of the herbal product
The patient's inability to take oral form
The patients with serious underlying disease at the same time, including high blood pressure, heart disease, lung disease, cerebral disease, diabetes.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Temperature. Timepoint: 0-1-2-3-4-5-6-7 days after starting intervention. Method of measurement: Mercury thermometer.;Cough severity. Timepoint: 1th and 7th dady after starting intervention. Method of measurement: cough severity score 1-4.;Respiratory rate. Timepoint: 0-1-2-3-4-5-6-7 days after starting intervention. Method of measurement: Counting the number of breaths per minute.;Dyspnea severity. Timepoint: 0-1-2-3-4-5-6-7 days after starting intervention. Method of measurement: Dyspnea severity score 1-4.;O2 saturation percentage. Timepoint: pulse oximetry at baseline, 1-2-3-4-5-6-7 days after starting intervention. Method of measurement: pulse oximeter.;White blood cell count. Timepoint: baseline and day 7 after starting intervention. Method of measurement: WBC counting under the microscope.
- Secondary Outcome Measures
Name Time Method